- Home
- EYPT vs DDL Comparison
EYPT vs DDL Comparison
Compare EYPT & DDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EYPT | DDL |
|---|---|---|
| Founded | 1987 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Catalog/Specialty Distribution |
| Sector | Industrials | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 419.9M | 494.2M |
| IPO Year | 2005 | 2021 |
Fundamental Metrics
Financial Performance| Metric | EYPT | DDL |
|---|---|---|
| Price | $4.62 | $2.26 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $31.80 | N/A |
| AVG Volume (30 Days) | ★ 6.3M | 279.1K |
| Earning Date | 05-06-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,539,000.00 | N/A |
| Revenue This Year | N/A | $7.06 |
| Revenue Next Year | $3,115.57 | $14.86 |
| P/E Ratio | ★ N/A | $16.08 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.95 | $1.65 |
| 52 Week High | $19.11 | $3.41 |
Technical Indicators
Market Signals| Indicator | EYPT | DDL |
|---|---|---|
| Relative Strength Index (RSI) | 29.97 | 45.14 |
| Support Level | $3.95 | $2.19 |
| Resistance Level | $15.17 | $2.25 |
| Average True Range (ATR) | 0.51 | 0.10 |
| MACD | -0.08 | -0.01 |
| Stochastic Oscillator | 26.30 | 15.00 |
Price Performance
Historical ComparisonAbout EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.
About DDL Dingdong (Cayman) Limited (each two representing three)
Dingdong (Cayman) Ltd are a foremost fresh grocery e-commerce company in mainland China with sustainable growth. It directly provide users and households with fresh groceries, prepared food and other food products through delivering a convenient and excellent shopping experience supported by an extensive self-operated frontline fulfillment grid. The Group operates and manages its business as a single segment. The Group generates substantially all of its revenues from customers in the PRC.